Together Against IBD
Two Teams, One Vision, Multiple Drug Candidate Therapies
We’re committed to beating inflammatory disease, and our complementary strengths make us far more capable of doing so.
Through our research and development efforts, we will relentlessly pursue novel therapies that break through the efficacy ceiling as we strive to improve the lives of patients living with IBD.
scroll

Between us we have over 50 active trials investigating 11 separate potential therapies across multiple inflammatory disorders in various preclinical and clinical stages. These include one novel molecule currently in review by global regulatory agencies.
We’re also advancing IBD research. Gilead is working together with the Crohn’s and Colitis Foundation (CCF). As a member of IBD Plexus®, the CCF’s research information exchange platform, Gilead is contributing to the analysis of high-definition, multi-omic data using biosamples collected from patients with IBD.
And we’re just getting started.
GILEAD AND GALAPAGOS: FINDING ANSWERS TOGETHER.
Maximising our resources and collective thinking, we problem-solve across our global offices. And we’re not alone. We collaborate with external partners to develop innovative therapeutic approaches.